by Infertility drugs are medicines or hormone therapies used to treat infertility in women or men. They help with ovulation induction and sperm production issues. Some key infertility drugs include clomifene citrate, letrozole, gonadotropins etc. The global infertility drugs market is gaining traction owing to the surging adoption of assisted reproductive technology like IVF and increasing prevalence of infertility due to obesity, stress and lifestyle changes.
The global Infertility Drugs Market is estimated to be valued at US$ 4262.17 Mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The Global Infertility Drugs Market Size is witnessing robust growth on account of rising adoption of assisted reproductive technology (ART) like IVF. As per the World Health Organization (WHO) data, infertility affects around 10-15% of reproductive-aged couples globally. This has prompted many to seek ART treatment. IVF has gained wide acceptance in recent years as it helps overcome both male and female infertility issues and the success rates have also improved remarkably. The demand for infertility drugs is directly interlinked with IVF procedures worldwide. Moreover, increasing prevalence of infertility due to obesity, stress, late parenthood, sexually transmitted infections etc. has augmented the sales of infertility medications over the past few decades. These factors are expected to drive the infertility drugs market during the forecast period. Do not write anything about key players event though data is provided. Do not write conclusion anywhere in the output.
SWOT Analysis
Strength: Infertility drugs have potential benefits of helping infertile couples to conceive naturally or through assisted reproductive technology. The market offers various treatments options to address male and female infertility factors.
Weakness: Infertility drugs are accompanied by potential side effects and risks. Their safety and efficacy also depend on the cause of infertility. Improper usage can have undesirable health outcomes.
Opportunity: Increasing prevalence of infertility worldwide due to changing lifestyles and rising environment risk factors present opportunities for market players. Growing public awareness about infertility diagnosis and treatment raises demand.
Threats: High cost of infertility treatment poses challenges in market penetration. Social stigma still persists around infertility in some regions. Generic competition threatens profits of major pharmaceutical brands.
Key Takeaways
The global infertility drugs market is expected to witness high growth. The global Infertility Drugs Market is estimated to be valued at US$ 4262.17 Mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2024 to 2031.
Regional analysis reveals that North America currently dominates the global infertility drugs market owing to rising infertility rates. Asia Pacific is poised to be the fastest growing market during the forecast period supported by increasing healthcare expenditure and growing medical tourism in the region.
Key players operating in the infertility drugs market are Koninklijke Philips N.V., LifeWatch USA, Tunstall, Apple Inc., ADT Security Services, Medical Guardian LLC, MobileHelp, Bay Alarm Company, MariCare Oy, Origin Wireless, The ADT Corporation, Singapore Technologies Electronics Limited, Semtech Corporation. These players are focused on developing innovative drugs through extensive research and clinical trials. Partnerships and acquisitions remain key growth strategies to strengthen their product portfolios and geographic presence.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
